NetScientific PLC ProAxsis Gains CE Mark for its Respiratory Test
30 Setembro 2016 - 3:02AM
RNS Non-Regulatory
TIDMNSCI
NetScientific PLC
30 September 2016
NetScientific plc
("NetScientific" or the "Company" or the "Group")
ProAxsis Gains CE Mark for its Respiratory Test
- CE Mark allows ProAxsis to begin commercialisation in Europe
London, UK - 30 September 2016 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation Group, announces that its portfolio company,
ProAxsis, has successfully registered a CE Mark to enable
commercialisation of its novel ProteaseTag(R) Active Neutrophil
Elastase Immunoassay.
Commenting on the news, François R. Martelet, Chairman of
ProAxsis and Chief Executive Officer of NetScientific, said: "We
are delighted that ProAxsis has achieved a significant milestone in
successfully CE marking its novel ProteaseTag(R) Active Neutrophil
Elastase Immunoassay for chronic respiratory diseases. This will
help accelerate its commercialisation in the COPD and Cystic
Fibrosis markets.
"ProAxsis is now able to sell its immunoassay in the 28 member
states of the European Union, as well as Switzerland, Turkey,
Iceland, Norway and Liechtenstein. Achieving CE Mark for its
immunoassay demonstrates the Company's clear commitment to
delivering first-class quality products to physicians and their
patients who suffer from chronic respiratory diseases."
The full text of the announcement issued by ProAxsis on 29
September 2016 is as follows:
ProAxsis gains CE Mark for Active Neutrophil Elastase
Immunoassay
ProAxsis Limited (www.proaxsis.com) is pleased to announce that
it has successfully registered a CE Mark for its novel
ProteaseTag(R) Active Neutrophil Elastase Immunoassay. Neutrophil
elastase is a well-recognised biomarker of lung inflammation and
infection in chronic respiratory diseases such as Chronic
Obstructive Pulmonary Disease (COPD), cystic fibrosis and
bronchiectasis. The registration of a CE Mark indicates that the
ProteaseTag(R) Active Neutrophil Elastase Immunoassay complies with
EU legislation, and enables the company to commercialise the
Immunoassay throughout the European market.
Commenting on the news, Dr David Ribeiro, CEO of ProAxsis, said:
"This is a very proud day for everyone at ProAxsis, with the
successful registration of our first CE Mark. We have already had
enquiries from a number of pharmaceutical companies concerning the
commercial use of our ProteaseTag(R) Active Neutrophil Elastase
Immunoassay in their upcoming clinical trials, and look forward to
making the assay more widely available to the respiratory community
now that it has its CE Mark. I would particularly like to
acknowledge the work of Dr Charlene Robb, who has led the
regulatory efforts that have enabled us to reach this significant
milestone."
Any queries concerning ProAxsis' Immunoassay for measuring
active neutrophil elastase, or any requests for support with
measuring other active protease biomarkers using the Company's
proprietary ProteaseTag(R) technology, can be directed to
info@proaxsis.com.
- Ends -
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite, CFO
Consilium Strategic Tel: +44 (0)20 3709 5700
Communications netscientific@consilium-comms.com
Mary-Jane Elliott /
Chris Gardner /
Jessica Hodgson / Chris
Welsh /
Laura Thornton
About NetScientific Plc
NetScientific is a transatlantic healthcare IP commercialisation
group focused on improving the health and well-being of people with
chronic diseases.
For more information, please visit the website at
www.netscientific.net
About ProAxsis Limited
ProAxsis is developing a range of products for the capture,
detection and measurement of active protease biomarkers of
diseases. This test measures Neutrophil Elastase, a leading
indicator of infection in patients with Cystic Fibrosis (CF) and
Chronic Obstructive Pulmonary Disease (COPD) and an important drug
target. The rapid and easy-to-use tests incorporate patented
ProteaseTags(R); smart molecules which trap an active protease
within a complex biological sample and enable a visual readout of
its presence. ProteaseTags(R) provide a unique tool to identify and
quantify active protease biomarkers and will assist in the clinical
validation of new therapeutics.
ProAxsis is part of the NetScientific Group and is one of the
Group's core portfolio companies. The company is also supported by
QUBIS, the commercialisation arm of Queens University.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFERALIAFIR
(END) Dow Jones Newswires
September 30, 2016 02:02 ET (06:02 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024